Tremelimumab Clinical Trials
34 recruitingDrug
Phase 222Phase 37Phase 17Early Phase 11
Showing 1–20 of 34 trials
Recruiting
Phase 1
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
Solid Tumours
AstraZeneca40 enrolled19 locationsNCT07391670
Recruiting
Phase 2
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaInvasive Breast Carcinoma
National Cancer Institute (NCI)70 enrolled30 locationsNCT03606967
Recruiting
Phase 1
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma+2 more
Mayo Clinic16 enrolled1 locationNCT06058663
Recruiting
Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca1,220 enrolled217 locationsNCT06921785
Recruiting
Phase 1
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins25 enrolled1 locationNCT06564623
Recruiting
Phase 2
Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
Hepatocellular Carcinoma Non-resectable
Center Eugene Marquis80 enrolled6 locationsNCT07122089
Recruiting
Phase 3
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Non-small Cell Lung CancerNSCLCNSCLC Stage III
Maximilian Diehn48 enrolled1 locationNCT04585490
Recruiting
Phase 3
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Advanced Hepatocellular Carcinoma
NRG Oncology226 enrolled107 locationsNCT07166406
Recruiting
Phase 1
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Hepatocellular Carcinoma
University of California, San Diego20 enrolled1 locationNCT06710223
Recruiting
Phase 1Phase 2
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Urothelial CarcinomaBladder Cancer
Noah Hahn, M.D.55 enrolled12 locationsNCT03317158
Recruiting
Phase 2
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma
City of Hope Medical Center535 enrolled13 locationsNCT07288034
Recruiting
Phase 2
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Georgetown University18 enrolled4 locationsNCT04499053
Recruiting
Early Phase 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Phase 2
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Hepatocellular Carcinoma Non-resectableHCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest55 enrolled12 locationsNCT04522544
Recruiting
Phase 2
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+1 more
Emory University39 enrolled4 locationsNCT07174570
Recruiting
Phase 1Phase 2
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Colorectal, CancerGastric CancerHepatocellular Carcinoma+1 more
Anwaar Saeed117 enrolled2 locationsNCT03539822
Recruiting
Phase 2
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
Hepatocellular CarcinomaCirrhosis, Liver
The University of Texas Health Science Center at San Antonio32 enrolled1 locationNCT06526104
Recruiting
Phase 2
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca114 enrolled24 locationsNCT07081633
Recruiting
Phase 2
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8+4 more
Mary Feng, MD21 enrolled1 locationNCT04430452
Recruiting
Phase 2
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Hepatocellular Carcinoma
Anwaar Saeed40 enrolled3 locationsNCT06698250